Assessing NOS Uptake With PET Imaging in Lung Inflammation

Assessing [18F](+/-)NOS Uptake With PET Imaging in Endotoxin-induced Lung Inflammation

The purpose of this study is to learn more about the basic responses of the lungs to inflammation using positron emission tomography, or PET, imaging scans of the lungs. PET is a machine that detects radiation and generates pictures using a donut-shaped scanner similar in appearance to an x-ray "CAT" or computed tomography (CT) scan or an MRI. Inflammation is the way our bodies react to irritation or injury, and involves red, warm, and often painful swelling of the affected tissue. An enzyme called inducible nitric oxide synthase (iNOS) contributes to the development of lung inflammation.

Study Overview

Detailed Description

The investigators plan to use three radioactive tracers to produce the PET images for measuring lung inflammation: [18F](+/-)NOS (the F stands for fluorine and NOS stands for Nitric Oxide Synthase, which targets iNOS), O-15 carbon monoxide ([15O]CO), and O-15 water ([15O]H2O). The NOS tracer gives information specifically about lung inflammation, while the carbon monoxide and water tracers give information about whether the lung inflammation causes more blood or water to be retained in the area of lung inflammation.

In order to show that [18F](+/-)NOS-PET is related to the amount of inflammation, the investigators first need to create a state of controlled lung inflammation that can be measured and quantified. "Controlled lung inflammation" means a reaction in the lungs that is similar to that which occurs during lung infection (increased respiratory secretions and cough). It is "controlled" because the investigators will not be using anything alive or contagious (it does not spread from one part of the body to another, and cannot spread to another person), and a small area in only one lung will be affected. In order to created this state of controlled lung inflammation, the investigators plan to place a small amount of a purified bacterial substance called endotoxin into a single small section of the lung using a bronchoscope (a long, flexible narrow tube that is passed through the mouth into the airways of the lung). This use of endotoxin is considered investigational, and the investigators have received permission from the FDA to use endotoxin in this research study.

Study Type

Interventional

Enrollment (Actual)

3

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • Saint Louis, Missouri, United States, 63110
        • Washington University School of Medicine / Barnes-Jewish Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 44 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy man or woman, any race or ethnicity, age 19-44 years old
  • Screening FEV1 and FVC greater than or equal to 90% of predicted
  • Screening oxygen saturation by pulse oximetry greater than or equal to 97% on room air
  • Capable of lying still and supine with arms raised above the head within PET/CT scanner for 2-2.5 hours
  • Capable of following instructions for breathing protocol during CT portion of PET/CT scans
  • Able and willing to give informed consent
  • Body Mass Index (BMI) < 35

Exclusion Criteria:

  • Pregnancy (confirmed by qualitative serum hCG pregnancy test)
  • Lactation
  • History of cardiopulmonary disease
  • Currently taking any prescription medications
  • History of tobacco use or illicit drug use within the past year
  • Presence of implanted electronic medical device
  • Enrollment in another research study of an investigational drug
  • Known allergy to both trimethoprim/sulfamethoxazole and amoxicillin, Penicillin, Lidocaine, Demerol, Versed, and/or Fentanyl
  • Inability to lie flat for 2-2.5 hours for PET/CT scans or follow breathing protocol instructions for the CT portion of the PET/CT
  • Prior research-related radiation exposure within the past year such that participation in this study would result in exposures that exceed the limits as defined by the FDA RDRC regulations (21 CFR 361.1)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Endotoxin and [18F](+/-)NOS
All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer [18F](+/-)NOS.
The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
Other Names:
  • Lipopolysaccharide
7 mCi of [18F](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Distribution volume ratio (DVR), determined by Logan plot analysis, in the right middle lobe
Time Frame: Change in DVR on post-endotoxin PET scan (Day 2) from baseline (Day 1)
Comparison of DVR by Logan plot for [18F](+/-)NOS uptake, pulmonary blood flow (PBF) and extravascular lung water (EVLW) in the regions of interest generated from scans obtained before and after endotoxin instillation and in the right and left lungs will be compared using a repeated-measures t-test, with statistical significance set at p<0.05. The DVR determined for [18F](+/-)NOS normalized for either PBF or EVLW will also be compared using a repeated-measures t-test before and after endotoxin as well as in the right and left lungs to determine whether differences in [18F](+/-)NOS uptake depend on either PBF or EVLW.
Change in DVR on post-endotoxin PET scan (Day 2) from baseline (Day 1)

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in DVR in right middle lobe
Time Frame: post-endotoxin scan (Day 2) from baseline (Day 1) scan
post-endotoxin scan (Day 2) from baseline (Day 1) scan
Mean Hounsfield units (HU), measure of density on CT images, in right middle lobe and lingula
Time Frame: baseline PET/CT scan on Day 1 to post-endotoxin scan on Day 2
baseline PET/CT scan on Day 1 to post-endotoxin scan on Day 2
Change in HU in right middle lobe and lingula
Time Frame: before and after endotoxin instillation (Day 1 to Day 2)
before and after endotoxin instillation (Day 1 to Day 2)
Bronchoalveolar lavage (BAL) cell counts (including total nucleated and neutrophil counts)
Time Frame: 6 hours post-endotoxin instillation
6 hours post-endotoxin instillation
Number and percent of iNOS-stained BAL cells by flow cytometry
Time Frame: 6 hours post-endotoxin instillation
6 hours post-endotoxin instillation
Number and percent of 3-nitrotyrosine-stained cells on biopsy
Time Frame: 6 hours post-endotoxin instillation
6 hours post-endotoxin instillation
Change in exhaled nitric oxide (ENO) levels
Time Frame: before and after endotoxin instillation (Day 1 to Day 2)
before and after endotoxin instillation (Day 1 to Day 2)
Regional PBF and EVLW in right middle lobe and lingula
Time Frame: before and after endotoxin (Day 1 to Day 2)
before and after endotoxin (Day 1 to Day 2)
Number of iNOS positive cells from brushing cytospins
Time Frame: 6 hours post-endotoxin instillation
6 hours post-endotoxin instillation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Delphine Chen, MD, Washington University School of Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2014

Primary Completion (Actual)

February 1, 2018

Study Completion (Actual)

February 1, 2018

Study Registration Dates

First Submitted

May 28, 2014

First Submitted That Met QC Criteria

May 28, 2014

First Posted (Estimate)

May 30, 2014

Study Record Updates

Last Update Posted (Actual)

July 23, 2018

Last Update Submitted That Met QC Criteria

July 19, 2018

Last Verified

July 1, 2018

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Inflammation

Clinical Trials on Endotoxin (E. coli O:113, Reference Endotoxin)

Subscribe